This course is part of the Lung Health Updates for Primary Care Providers: Conversations with NHLBI curriculum.
0.25 CME/CE Credit
Pulmonary Fibrosis: What Primary Care Providers Need to Know
“Pulmonary Fibrosis: What Primary Care Providers Need to Know” is a CME podcast episode produced by Pri-Med in partnership with Learn More Breathe Better®, a program of the National Heart, Lung, and Blood Institute of the National Institutes of Health. In this episode, we are joined by Dr. Matt Craig, Chief of the Lung Biology and Disease Branch with NHLBI’s Division of Lung Diseases, and Dr. Fernando J. Martinez, Chief of the Pulmonary and Critical Care Medicine Division at Weill Cornell Medicine. Today we’ll be discussing pulmonary fibrosis and the role of primary care providers, including signs to look out for, diagnosis, and treatment options.
Already listened on another platform?
- Explore the role that PCPs can play in identifying pulmonary fibrosis, enabling diagnosis, and assessing disease severity
- Examine the symptoms and risk factors for pulmonary fibrosis
- Discuss the diagnosis and treatment of pulmonary fibrosis
Fernando J. Martinez, MD
Chief of the Pulmonary and Critical Care Medicine Division
Weill Cornell Medicine
Matt Craig, Ph.D.
National Heart, Lung, and Blood Institute
National Institutes of Health
The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.
Fernando J Martinez, MD, MS: Speaker for Boehringer Ingelheim; Advisor for Boehringer Ingelheim, DevPro, Excalibur, Lung Therapeutics; Researcher for Boehringer Ingelheim, Biogen, Bristol Myers Squibb, DevPro, Novartis, Nitto, Roche.
John Matthew Craig, Ph.D.: No relevant financial relationships disclosed.
Vani Potluri, MD (moderator): No relevant financial relationships disclosed.
Non-faculty contributors involved in the planning, development, editing, and review of the content have disclosed no relevant financial relationships.
AMA PRA Category 1 Credits
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Pri-Med Institute designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose personal financial relationships with commercial interests or ineligible companies prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to mitigate real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. All relevant financial relationships have been mitigated Financial disclosures for everyone in control of educational content are provided before the start of each CME/CE activity.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions? If you have questions about this activity, please email firstname.lastname@example.org or call (877) 477-4633.